statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences Genprex to Present and Participate at Upcoming May Investor and Industry Conferences PR Newswire AUSTIN, Texas...

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR...

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

HC Wainwright reissued their buy rating on shares of Genprex (NASDAQ:GNPX - Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a $10.00...

Genprex (NASDAQ:GNPX) Receives "Buy" Rating from HC Wainwright

Genprex, Inc. (NASDAQ:GNPX - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Genprex in a research report issued on Wednesday, April 3rd. HC...

Genprex, Inc. to Post Q1 2025 Earnings of ($0.86) Per Share, HC Wainwright Forecasts (NASDAQ:GNPX)

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer Genprex Expands Clinical Trial Sites for Acclaim-3...

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy...

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System

Genprex, Inc. (NASDAQ:GNPX  Free Report)  Equities research analysts at HC Wainwright issued their FY2023 earnings per share estimates for shares of Genprex in a report issued on...

Genprex, Inc. (NASDAQ:GNPX) Expected to Post FY2023 Earnings of ($24.10) Per Share

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market...

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Genprex to sell 1.54M shares at $4.215 in registered direct offering priced ATM

Genprex announces $6.5M registered direct offering priced at the market

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Watchers	12,358
52-Wk Low	$2.09
52-Wk High	$42.40

Volume	31,476.00
52-Wk High	$42.40
52-Wk Low	$2.09

GNPX Genprex Inc

About

Feed

News

Sentiment

Earnings

Fundamentals